Trastuzumab Rezetecan for advanced solid tumors that have stopped responding to standard treatments
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called Trastuzumab Rezetecan in people with advanced solid tumors that are HER2-positive and have not responded to standard therapies. It includes three specific groups: people with extramammary Paget's disease, rare solid tumors, or urothelial carcinoma. The goal is to see if this drug can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your tumor must be HER2-positive (a protein on the surface of some cancer cells).
- You must have one of three specific types of advanced cancer that has not responded to standard treatment.
- You must have a tumor that can be measured on a CT scan.
- Your blood counts, liver and kidney function, and clotting must be within certain ranges.
- You must not have certain severe or uncontrolled medical conditions, such as poorly controlled high blood pressure, heart problems, active infections, or untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called trastuzumab rezetecan for people with advanced solid tumors that show a certain protein (HER2). The drug targets HER2 to help kill cancer cells, and the goal is to see if it is safe and effective.
This trial tests a new drug, Trastuzumab-rezetecan, in people with breast cancer that has a certain amount of a protein called HER2. It aims to see if the drug works and is safe for patients who are able to receive it before or after surgery, or for those whose cancer has spread and has been treated before.
This trial tests a new drug, trastuzumab rezetecan, for women with breast cancer that has come back or spread and cannot be removed by surgery. It's for those who haven't had chemotherapy for advanced disease but have tried hormone therapy and it stopped working.
This trial tests a new drug combination for people with advanced bladder cancer that has a protein called HER2 on its surface. It may help those whose cancer has spread or cannot be removed with surgery. The study looks at the drug given alone or with an immunotherapy.
This study tests a combination of an existing targeted drug (trastuzumab) and a new experimental drug (retlirafusp alfa) for advanced stomach cancer that has a specific marker (HER2) and did not respond to initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests a new antibody-drug combination (trastuzumab rezetecan, also called T-DXd) for patients with HER2-positive breast cancer whose tumor did not fully disappear after initial chemotherapy. The goal is to see if this drug can reduce the risk of cancer coming back.
Hear when a new Urachal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.